Squamous cell carcinoma transformation after acquired resistance to osimertinib in a patient with lung adenocarcinoma harboring uncommon EGFR mutation

J Formos Med Assoc. 2020 Sep;119(9):1439-1441. doi: 10.1016/j.jfma.2019.12.017. Epub 2020 Mar 12.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acrylamides / therapeutic use*
  • Adenocarcinoma of Lung / drug therapy*
  • Adenocarcinoma of Lung / epidemiology
  • Adenocarcinoma of Lung / genetics
  • Aniline Compounds / therapeutic use*
  • Carcinoma, Squamous Cell / drug therapy*
  • Carcinoma, Squamous Cell / genetics
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics*
  • ErbB Receptors / drug effects*
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics
  • Middle Aged
  • Mutation / drug effects
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Acrylamides
  • Aniline Compounds
  • Protein Kinase Inhibitors
  • osimertinib
  • EGFR protein, human
  • ErbB Receptors